Tag: DES
BIOMAG-I two year results confirm safety and efficacy of Biotronik resorbable...
New two-year follow-up data from the BIOMAG-I first-in-human trial confirms a reliable and predictable long-term safety profile for Freesolve, the third-generation resorbable magnesium scaffold...
SAVAL trial finds no gains with custom drug-eluting stents in PAD...
Day one of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14 September, Barcelona, Spain) put a strong focus on...
EMINENT one-year results show “superior” primary patency rate for Eluvia DES...
One-year results presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA) from the EMINENT trial demonstrated the superiority of the Eluvia...
New meta-analysis finds “no observed difference” in mortality between paclitaxel and...
February 2020 brings another paclitaxel device meta-analysis of randomised controlled trials in chronic limb-threatening ischaemia (CLTI) patients. Krystal Dinh (Westmead Hospital, Sydney, Australia) et...
VIVA 2019: Boston Scientific announces positive data for the Ranger DCB...
Boston Scientific today announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at the 2019...
CIRSE 2019: Hear the latest from clinical trials comparing paclitaxel technologies...
NOTE: ONLY intended for healthcare professionals outside of the USA and France.
Zoom in on a tête-à-tete between Marianne Brodmann (Graz, Austria) and Giovanni Torsello...
Sirolimus has “a much wider” safety window and shows fewer local...
Paclitaxel kills the cells in the artery wall; sirolimus simply stuns them. So says Peter Gaines (Sheffield, UK) at VLF 2019 while commenting on...
Customising therapy in femoropopliteal revascularisation
Gary Ansel (Columbus, USA) tells Vascular News at VEITHSymposium 2018 about how drug-based therapies have become a mainstay in femoropopliteal revascularisation and how interventionalists...
Meta-analysis finds a higher risk of death in the long term...
Konstantinos Katsanos (Patras, Greece) tells Interventional News about new data from a meta-analysis that has been published in the Journal of the American Heart...
Meta-analysis finds a higher risk of death in the long term...
New data, just published in the Journal of the American Heart Association (JAHA), suggest that there is an increased risk of death at two...
Lutonix registry data confirm durability of drug-coated balloon treatment in superficial...
The 24-month results of the worldwide experience with Lutonix 035 drug-coated balloon (CR Bard/Beckton Dickenson) were published online in August in JACC: Cardiovascular Interventions....
DANCE data boost for dexamethasone use after revascularisation in femoropopliteal arteries
While drug-eluting devices, be they balloons or stents, use chemotherapeutic agents (usually paclitaxel) to reduce the build-up of scar tissue inside the arteries, a...
